CA3169057A1 - Modulateurs de kv3 - Google Patents

Modulateurs de kv3

Info

Publication number
CA3169057A1
CA3169057A1 CA3169057A CA3169057A CA3169057A1 CA 3169057 A1 CA3169057 A1 CA 3169057A1 CA 3169057 A CA3169057 A CA 3169057A CA 3169057 A CA3169057 A CA 3169057A CA 3169057 A1 CA3169057 A1 CA 3169057A1
Authority
CA
Canada
Prior art keywords
benzofuran
dione
disorders
compound
cyclopropane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3169057A
Other languages
English (en)
Inventor
Giuseppe Alvaro
Agostino Marasco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autifony Therapeutics Ltd
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of CA3169057A1 publication Critical patent/CA3169057A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Un composé de formule (I)dans lequelR1 est H ou un méthyleR2 et R3 sont tous deux des méthyles ou R2 et R3 conjointement avec l'atome de carbone auquel ils sont fixés sont une bague de spirocyclopropyle.R4 est un methyl ou un éthyl; R5 est H ou un méthyl;ou R4 et R5 - conjointement avec l'atome de carbone auquel ils sont fixés - forment un spiro carbocyclyl C3-C4ou un sel, solvate, ou dérivé connexeest décrit pour la prophylaxie ou le traitement des troubles de l'audition, y compris la perte auditive et les acouphènes, ainsi que la schizophrénie, les troubles liés à la toxicomanie, la douleur et le syndrome de l'X fragile.
CA3169057A 2020-02-06 2020-02-06 Modulateurs de kv3 Pending CA3169057A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2020/050268 WO2021156584A1 (fr) 2020-02-06 2020-02-06 Modulateurs de kv3

Publications (1)

Publication Number Publication Date
CA3169057A1 true CA3169057A1 (fr) 2021-08-12

Family

ID=69591671

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3169057A Pending CA3169057A1 (fr) 2020-02-06 2020-02-06 Modulateurs de kv3

Country Status (11)

Country Link
EP (1) EP4100402A1 (fr)
JP (1) JP2023523501A (fr)
KR (1) KR20220139923A (fr)
CN (1) CN115066424A (fr)
AU (1) AU2020427632A1 (fr)
BR (1) BR112022013339A2 (fr)
CA (1) CA3169057A1 (fr)
CL (1) CL2022002081A1 (fr)
IL (1) IL295027A (fr)
MX (1) MX2022009702A (fr)
WO (1) WO2021156584A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117448440A (zh) * 2023-10-23 2024-01-26 中国人民解放军空军军医大学 Kv3在制备诊断或治疗创伤后应激障碍异常恐惧记忆消退产品中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5788404B2 (ja) 2009-12-11 2015-09-30 アウトイフオンイ トヘラペウトイクス リミテッド イミダゾリジンジオン誘導体
AU2011340258C1 (en) 2010-12-06 2016-10-20 Autifony Therapeutics Limited Hydantoin derivatives useful as Kv3 inhibitors
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
PL2788339T3 (pl) 2011-12-06 2016-09-30 Pochodne hydantoiny przydatne jako inhibitory KV3
BR112014028991A2 (pt) 2012-05-22 2017-06-27 Autifony Therapeutics Ltd triazóis como inibidores de kv3
WO2013175211A1 (fr) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Dérivés d'hydantoïne en tant qu'inhibiteurs de kv3
WO2013182851A1 (fr) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxie ou traitement de maladies dans lesquelles un modulateur des canaux kv3.3 est requis
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) * 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
US20200039970A1 (en) 2016-12-16 2020-02-06 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
CA3110251A1 (fr) 2018-09-21 2019-11-28 Bionomics Limited Composes substitues par pyridinyle et leurs utilisations
MX2021004386A (es) * 2018-10-16 2021-06-04 Autifony Therapeutics Ltd Compuestos novedosos.
EP3947365A4 (fr) 2019-03-25 2022-08-24 Bionomics Limited Composés n-hétéroaryle substitués et leurs utilisations

Also Published As

Publication number Publication date
WO2021156584A1 (fr) 2021-08-12
CN115066424A (zh) 2022-09-16
JP2023523501A (ja) 2023-06-06
EP4100402A1 (fr) 2022-12-14
KR20220139923A (ko) 2022-10-17
IL295027A (en) 2022-09-01
BR112022013339A2 (pt) 2022-09-13
MX2022009702A (es) 2022-09-07
CL2022002081A1 (es) 2023-05-26
AU2020427632A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
US11541052B2 (en) Compounds
US11180461B2 (en) Triazoles as Kv3 inhibitors
US9193704B2 (en) Hydantoin derivatives as KV3 inhibitors
EP3490977B1 (fr) Dérivés cyclobutane comme modulateurs des canaux potassiques voltage-dépendants
CA2856654C (fr) Derives d'hydantoine utiles comme inhibiteurs de kv3
JP2019502696A (ja) Ｋｖ３チャネルのヒダントインモジュレーター
TWI827706B (zh) 新穎化合物
WO2013182850A1 (fr) Modulateurs des canaux potassium kv3 à base de dérivés d'isobenzofuran- 5-yl-oxy(hétéro)aryl-imidazolidine-2,4-dione pour traiter les troubles du snc
US20200039970A1 (en) Hydantoin modulators of kv3 channels
CA3169057A1 (fr) Modulateurs de kv3
US20210276985A1 (en) Novel compounds
WO2023017263A1 (fr) Modulateurs des canaux potassiques

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920